Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Mark HollywoodEVP & COO | ZymeworksZYME | Open-market sale | 01/12 | 01/13 | 6,120 sh | $22.67 | $138,740.4 | −4.4% |
Galbraith KennethChair & CEO | ZymeworksZYME | Open-market sale | 01/12 | 01/12 | 30,424 sh | $22.67 | $689,712.08 | −11.8% |
Smith Jeffrey T. L.EVP & Chief Medical Officer | ZymeworksZYME | Open-market sale | 01/12 | 01/12 | 9,310 sh | $22.67 | $211,057.7 | −25.8% |
Moore Paul AndrewChief Scientific Officer | ZymeworksZYME | Open-market sale | 01/12 | 01/12 | 9,560 sh | $22.67 | $216,725.2 | −16.5% |
ZymeworksZYME | Open-market sale | 01/05 | 01/05 | 54,343 sh2 trades | $25.10avg. | $1,364,009.3 | −21.9% | |
Smith Jeffrey T. L.EVP & Chief Medical Officer | ZymeworksZYME | Open-market sale | 01/05 | 01/05 | 10,538 sh | $25.10 | $264,503.8 | −36.5% |
ZymeworksZYME | Open-market sale | 01/05 | 01/05 | 20,110 sh2 trades | $25.10avg. | $504,761 | −33.2% | |
Galbraith KennethChair & CEO | ZymeworksZYME | Open-market sale | 25/12/22 | 25/12/22 | 47,528 sh | $27.02 | $1,284,206.56 | −26.3% |
ZymeworksZYME | Open-market buy | 25/05/15–25/05/19 | 25/05/19 | 55,421 sh2 trades | $11.47avg. | $635,533.68 | +0.3% | |
ZymeworksZYME | Open-market buy | 25/05/15–25/05/19 | 25/05/19 | 55,421 sh2 trades | $11.47avg. | $635,533.68 | +0.3% | |
ZymeworksZYME | Open-market buy | 25/04/16–25/04/17 | 25/04/18 | 128,713 sh2 trades | $11.31avg. | $1,456,150.68 | +0.7% | |
ZymeworksZYME | Open-market buy | 25/04/16–25/04/17 | 25/04/18 | 128,713 sh2 trades | $11.31avg. | $1,456,150.68 | +0.7% | |
ZymeworksZYME | Open-market buy | 25/04/03–25/04/04 | 25/04/07 | 317,208 sh2 trades | $11.43avg. | $3,624,129.26 | +1.8% | |
ZymeworksZYME | Open-market buy | 25/04/03–25/04/04 | 25/04/07 | 317,208 sh2 trades | $11.43avg. | $3,624,129.26 | +1.8% | |
ZymeworksZYME | Open-market buy | 25/03/31–25/04/02 | 25/04/02 | 127,415 sh3 trades | $11.75avg. | $1,497,263.55 | +0.7% | |
ZymeworksZYME | Open-market buy | 25/03/31–25/04/02 | 25/04/02 | 127,415 sh3 trades | $11.75avg. | $1,497,263.55 | +0.7% | |
ZymeworksZYME | Open-market buy | 25/03/25–25/03/26 | 25/03/27 | 97,349 sh2 trades | $12.61avg. | $1,227,397.43 | +0.6% | |
ZymeworksZYME | Open-market buy | 25/03/25–25/03/26 | 25/03/27 | 97,349 sh2 trades | $12.61avg. | $1,227,397.43 | +0.6% | |
ZymeworksZYME | Open-market buy | 25/03/20–25/03/24 | 25/03/24 | 127,198 sh3 trades | $12.92avg. | $1,643,418.54 | +0.7% | |
ZymeworksZYME | Open-market buy | 25/03/20–25/03/24 | 25/03/24 | 127,198 sh3 trades | $12.92avg. | $1,643,418.54 | +0.7% |